• Dicembre 2024 – Collaborazione tra AIFA, AIOM, CIPOMO e FICOG, per lo sviluppo scientifico dei dati contenuti nel Registro di Monitoraggio di pazopanib per il trattamento del sarcoma dei tessuti molli. Sulla rivista ESMO Open è disponibile la pubblicazione dal titolo: “Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry”. L’analisi statistica ha riguardato una coorte di pazienti affetti da sarcoma dei tessuti molli. L’obiettivo dell’analisi era quello di caratterizzare i pazienti trattati con pazopanib nella pratica clinica e verificare l’associazione tra tempo alla discontinuazione e sottotipo istologico.

Recent observational studies from Pubmed (limit 1 year, medication adherence OR persistence)

• Palbociclib
• Ribociclib
• Abemaciclib

• Alectinib
• Lorlatinib
• Brigatinib

• Atezolizumab
• Durvalumab

Palbociclib

• Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience
  November 29, 2025 by Onur Baş
• Assessing the Influence of Proton Pump Inhibitors on Clinical Outcomes in Hormone Receptor-Positive Metastatic Breast Cancer Patients Receiving CDK4/6 Inhibitors: Evidence from a Ribociclib-Dominant Cohort
  November 27, 2025 by Enes Erul
• Clinical significance on switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancer
  October 12, 2025 by Takuya Nishina
• Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2- metastatic breast cancer: A Flatiron Health database analysis
  March 26, 2025 by Rachel M Layman

Ribociclib

• Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience
  November 29, 2025 by Onur Baş
• Assessing the Influence of Proton Pump Inhibitors on Clinical Outcomes in Hormone Receptor-Positive Metastatic Breast Cancer Patients Receiving CDK4/6 Inhibitors: Evidence from a Ribociclib-Dominant Cohort
  November 27, 2025 by Enes Erul

Abemaciclib

• Impact of Abemaciclib-Induced Serum Creatinine Elevation on Dose Adjustment of Concomitant Medications
  October 23, 2025 by Kengo Umehara
• Clinical significance on switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancer
  October 12, 2025 by Takuya Nishina
• Real-world treatment outcomes of abemaciclib in older patients with HR+, HER2- metastatic breast cancer in Japan
  September 15, 2025 by Tatsunori Shimoi
• Real-World Toxicity and Effectiveness Study of Abemaciclib in Greek Patients with Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Multi-Institutional Study
  August 14, 2025 by Elena Fountzilas
• Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2- Breast Cancer
  March 28, 2025 by Maria Rosaria Valerio

top page

Alectinib

• Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study
  December 10, 2025 by Haoran Zhang
• Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer
  August 30, 2025 by Rahul Mudumba
• Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements
  February 10, 2025 by Kyuhwan Kim

Lorlatinib

• Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer
  August 30, 2025 by Rahul Mudumba
• Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China
  May 16, 2025 by Guangming Tian

Brigatinib

• Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer
  August 30, 2025 by Rahul Mudumba
• Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements
  February 10, 2025 by Kyuhwan Kim

top page

Atezolizumab

• Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression 50%: real-world data from the italian ATLAS registry
  December 24, 2025 by Francesco Passiglia
• Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
  December 1, 2025 by Pasquale Lombardi
• Clinical Outcomes of Reduced-Dose Cabozantinib as Third- or Later-Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real-World Study
  November 27, 2025 by Teiji Kuzuya
• PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort study
  October 27, 2025 by Hugo Jourdain
• Randomized phase II study comparing two doses of regorafenib in second-line treatment for advanced hepatocellular carcinoma
  October 1, 2025 by Keisuke Koroki

Durvalumab

• Timing of Durvalumab Consolidation and Survival in Non-Small Cell Lung Cancer: A Population-Based Analysis
  December 10, 2025 by Tawee Tanvetyanon
• Durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in the Thai population: a real-world, multicenter observational study
  November 7, 2025 by Piyada Sitthideatphaiboon
• PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort study
  October 27, 2025 by Hugo Jourdain
• First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study
  September 19, 2025 by Ioannis Kournoutas
• Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival
  May 11, 2025 by Ella A Eklund

top page